International Kidney Cancer Symposium

High-dose interleukin-2 (HD IL-2) continues to have a favorable safety profile compared with data in the original package insert.

Researchers are enrolling patients for part 2 of a phase 2 trial to compare dalantercept plus axitinib for treatment of renal cell carcinoma (RCC).

Final overall survival results of the RECORD-3 trial are consistent with results and support the standard sequence of sunitinib followed by everolimus.

Axitinib treatment may result in higher drug costs compared with everolimus.

A phase 2 trial is enrolling patients with renal cell carcinoma (mRCC) to compare the combination of axitinib plus TRC105 with axitinib alone.

Axitinib initiated at 5 mg twice daily resulted in toleration of higher daily doses with sustained efficacy in patients with metastatic renal cell carcinoma (mRCC).

Clinical outcomes with everolimus as a second targeted therapy were not significantly different in advanced renal cell carcinoma (aRCC).

A large percentage of real-world patients with metastatic renal cell carcinoma (mRCC) initially deferred systemic therapy.

Side effects with immunotherapy are different from, and in most cases of PD-1 inhibition, better than chemotherapy.

In a population-based setting, sunitinib and pazopanib have similar efficacy in first-line treatment of metastatic renal cell carcinoma (mRCC).